An overview of biosimilars
DOI:
https://doi.org/10.18203/2319-2003.ijbcp20243846Keywords:
Biosimilars, Follow-on biologics, Similar biologic medicinal products, Bio-therapeutical productsAbstract
The paradigm of pharmacological therapy in diseases is shifting from conventional small molecule drugs to biological drugs produced by living systems. Biological drugs have extensively ramified into therapies of various conditions such as autoimmune disorders, haematological conditions, cancers and others. Biological drugs are currently the diamond mine of the pharmaceutical drug market. Due to the enormous market value, other pharmaceutical companies are keen in producing and marketing generic versions of these innovator (reference) biologic companies, once the patents start to expire. These generic versions of the biological drugs are called as biosimilars. However, biosimilars are not exactly generics of the originator biological drugs like in the case of conventional small molecule drugs. Various controversies and perplexities exist in their production, approval, marketing, and prescription. The reason for the mere existence of biosimilars or generics drugs for that matter is their reduced cost with preserved clinical effectiveness. Biosimilar drugs are subject to rigorous scrutiny by a thorough comparative evaluation with the reference biological product for marketing approval. It is also equally important for the physicians and pharmacists to have a sound body of knowledge about biosimilar drugs to optimally avail the benefits offered by them. This review highlights how biosimilar drugs differ from the conventional drugs, their development process, issues, and challenges associated with their use.
Metrics
References
Simoens S. Biosimilar medicines and cost-effectiveness. Clinicoecon Outcomes Res. 2011;3:29-36.
FDA/CDER. Scientific considerations in demonstrating bio-similarity to a reference product guidance for industry. 2015. Available at: https://www.fda.gov/downloads. Accessed on 19 August 2024.
EMA. Biosimilars in the EU, information guide for healthcare professionals. Available at: https://www.ema.europa.eu/en. Accessed on 21 August 2024.
Gámez BR, Hernández CC, Arredondo AM, Aranda CJ, González R, Martínez AO, et al. Biosimilars: Concepts and controversies. Pharmacol Res. 2018;133:251–64.
Declerck P, Danesi R, Petersel D, Jacobs I. The Language of Biosimilars: Clarification, Definitions, and Regulatory Aspects. Drugs. 2017;77(6):671–77.
Blandizzi C, Galeazzi M, Valesini G. Transitioning from first- to second-generation biosimilars: An appraisal of regulatory and post-marketing challenges. Pharmacol Res. 2018;128:306–14.
Farhat F, Torres A, Park W, de Lima Lopes G, Mudad R, Ikpeazu C, et al. The concept of biosimilars: from characterization to evolution—a narrative review. The Oncolog. 2018;23(3):346–52.
Harvey RD. Science of Biosimilars. J Oncol Pract. 2017;13:17–23.
Moorkens E, Meuwissen N, Huys I, Declerck P, Vulto AG, Simoens S. The market of biopharmaceutical medicines: a snapshot of a diverse industrial landscape. Front Pharmacol. 2017;8:1-12.
Biosimilars: the pipeline seams seem to be bursting. Managed Care magazine. 2017. Available at: https://www.managedcaremag.com. Accessed on 23 August 2024.
EMA/CHMP. Guideline on similar biological medicinal products containing biotechnology- derived proteins as active substance: non-clinical and clinical issues. 2014. Available at: https://www.ema.europa.eu/en. Accessed on 22 August 2024.
FDA/CDER. Clinical pharmacology data to support a demonstration of bio-similarity to a reference product: guidance for industry. 2016. Available at: https://www.fda.gov/downloads/drugs. Accessed on 18 August 2024.
EMA/CHMP. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. 2007. Available at: https://www.ema.europa.eu/en/documents. Accessed on 19 August 2024.
FDA/CDER. Quality considerations in demonstrating bio-similarity to a reference protein product. 2015. Available at: www.fda.gov/downloads/drugs. Accessed on 29 August 2024.
EMA/CHMP. Guideline on similar biological medicinal products containing biotechnology- derived proteins as active substance: quality issues (revision 1). 2014. Available at: https://www.ema.europa.eu. Accessed on 25 August 2024.
FDA/CDER. Considerations in demonstrating interchangeability with a reference product guidance for industry. 2017. Available at: https://www.fda.gov/regulatory. Accesssed on 21 August 2024.
Young KE, Rémuzat C, Urbinati D, Toumi M. An overview of the biosimilar market in the US. Value Health. 2014;17(7):410.
Ramanan S, Grampp G. Drift, evolution, and divergence in biologics and biosimilars manufacturing. Bio Drugs. 2014;28(4):363–72.
Casadevall N, Edwards IR, Felix T, Graze PR, Litten JB, Strober BE, et al. Pharmacovigilance and biosimilars: considerations, needs and challenges. Expert Opin Biol Ther. 2013;13(7):1039–47.
Stevenson JG, Popovian R, Jacobs I, Hurst S, Shane LG. Biosimilars: practical considerations for pharmacists. Ann Pharmacother. 2017;51(7):590–602.
FDA/CDER. Labeling for biosimilar products guidance for industry. 2018. Available at: https://www.fda.gov/downloads/Drugs. Accessed on 12 August 2024.
Downloads
Published
How to Cite
Issue
Section
